Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

4350 Executive Drive, Suite 325, San Diego, United States

Merlintrader Aug. 19 at 12:06 PM

$ONCY On August 18 Oncolytics said the FDA has given written feedback on the design of a potential pivotal Part B of REO 033 in second-line RAS-mutant MSS colorectal cancer, with alignment on a possible accelerated approval path based on objective response rate and duration of response, and progression-free survival supporting full approval. No start date was disclosed. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/oncolytics-biotech-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=news-19ago2026

0 · Reply

GoPatzGo123 Aug. 19 at 11:12 AM

$ONCY $MRNA just announced breakthrough in Cancer treatment

3 · Reply

GoPatzGo123 Aug. 19 at 11:11 AM

$MRNA wow $ONCY

0 · Reply

FoxM07 Aug. 19 at 8:00 AM

$ONCY

0 · Reply

cbachand Aug. 19 at 3:05 AM

$ONCY https://www.youtube.com/watch?v=1JMZGq9fxaU

0 · Reply

saxy4u Aug. 19 at 2:36 AM

$ONCY honestly how basic are you that you need to repost an old post just because you are so stupid you can’t come up with something original to say. The Narcissistic 2 muppets are paid to banter with each other to ruin these boards for this stock. I don’t get why they are so pathetic in the effort on a Company who is trying to assist people on living longer. One is a paid poster to push other stock agendas and the other one is paid to bash and create hate and fear of loss so his shorters can stop sell raid. Ughhh

2 · Reply

saxy4u Aug. 19 at 2:03 AM

$ONCY @FoxM07 unfortunately is blocked, can’t deal with them anymore. GL everyone, private message me if you need anything, sorry they ruined this board!

1 · Reply

saxy4u Aug. 19 at 2:02 AM

$ONCY @Noteable_Ex unfortunately is blocked! Sorry guys I can deal with them anymore!

0 · Reply

Notable_Ex Aug. 19 at 1:06 AM

$ONCY Hey spamman, where are you now?

0 · Reply

FoxM07 Aug. 18 at 11:24 PM

$ONCY

0 · Reply

Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

2026-08-18T13:16:14.000Z - 23 hours ago

Oncolytics aligns with FDA on path for REO 033 expansion study

Aug 18, 2026, 9:00 AM EDT - 23 hours ago

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Oncolytics Biotech Quarterly report: Q2 2026

2026-07-20T13:06:01.000Z - 4 weeks ago

Oncolytics announces FDA Fast Track designation for pelareorep

Jul 20, 2026, 9:00 AM EDT - 4 weeks ago

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

2026-07-13T13:10:54.000Z - 5 weeks ago

Oncolytics provides clinical, regulatory update on REO 033

Jul 13, 2026, 9:00 AM EDT - 5 weeks ago

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

2026-06-16T13:38:20.000Z - 2 months ago

Oncolytics secures new patent for pelareorep manufacturing

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Oncolytics Biotech Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T14:21:34.000Z - 2 months ago

Oncolytics promotes John McAdory to COO

CGON

Jun 2, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

2026-06-01T13:47:40.000Z - 2 months ago

Oncolytics announces initial data from pelareorep combination study

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Oncolytics Biotech Slides: Investor presentation

2026-05-22T13:45:50.000Z - 3 months ago

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

May 22, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 14, 2026, 4:00 PM EDT - 3 months ago

Oncolytics Biotech Quarterly report: Q1 2026

May 4, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

2026-04-27T13:19:05.000Z - 4 months ago

Oncolytics says in alignment with FDA following pelareorep Type C meeting

Apr 27, 2026, 8:10 AM EDT - 4 months ago

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Oncolytics Biotech Slides: Investor presentation

2026-04-07T14:24:37.000Z - 4 months ago

Oncolytics price target lowered to $5 from $7 at Lake Street

2026-04-06T13:56:11.000Z - 4 months ago

Oncolytics schedules FDA meeting for pelareorep registrational path

Apr 6, 2026, 9:00 AM EDT - 4 months ago

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

2026-04-01T13:39:37.000Z - 4 months ago

Oncolytics completes domicile change to the U.S.

Apr 1, 2026, 9:00 AM EDT - 4 months ago

Oncolytics Biotech® Completes Domicile Change to the United States

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Oncolytics Biotech Registration statement: Registration filing

2026-04-01T10:11:38.000Z - 5 months ago

Oncolytics files $250M mixed securities shelf

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Oncolytics Biotech Annual report: Q4 2025

2026-03-19T13:16:47.000Z - 5 months ago

Oncolytics to present new data on Pelareorep at AACR 2026

Mar 19, 2026, 9:00 AM EDT - 5 months ago

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 3, 2026, 6:00 AM EST - 6 months ago

Oncolytics Biotech Slides: Corporate presentation

2026-03-02T14:12:44.000Z - 6 months ago

Oncolytics initiates randomized colorectal cancer study

Mar 2, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

2026-02-24T14:05:55.000Z - 6 months ago

Oncolytics concludes enrollment in GOBLET study

Feb 24, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

2026-02-04T13:55:27.000Z - 6 months ago

Oncolytics receives FDA Fast Track Designation for pelareorep

Feb 4, 2026, 8:50 AM EST - 6 months ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Jan 15, 2026, 4:01 PM EST - 7 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 10:00 AM EST - 7 months ago

Oncolytics Biotech Transcript: AGM 2026

2026-01-14T14:15:39.000Z - 7 months ago

Oncolytics appoints John McAdory as EVP, strategy and operations

CGON

Jan 14, 2026, 7:00 AM EST - 7 months ago

Oncolytics Biotech Slides: Investor presentation

2026-01-12T14:10:53.000Z - 7 months ago

Oncolytics announces updates data from GOBLET cohort 4

Jan 12, 2026, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

2026-01-09T14:05:19.000Z - 7 months ago

Oncolytics outlines strategic rationale for proposal to change jurisdiction

Jan 9, 2026, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 8, 2026, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 7, 2026, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Dec 16, 2025, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 9, 2025, 6:00 PM EST - 9 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Nov 20, 2025, 4:05 PM EST - 9 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Nov 19, 2025, 9:00 AM EST - 9 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Nov 11, 2025, 6:00 PM EST - 10 months ago

Oncolytics Biotech Earnings release: Q3 2025

Oct 28, 2025, 7:30 AM EDT - 10 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 10 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 1 year ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 22, 2025, 8:00 AM EDT - 1 year ago

Oncolytics Biotech Registration statement: Registration Filing

Aug 11, 2025, 4:55 PM EDT - 1 year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Transcript: AGM 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q2 2025

Aug 8, 2025, 9:05 AM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 1 year ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 1 year ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 1:00 PM EDT - 1 year ago

Oncolytics Biotech Transcript: Status Update

Jul 16, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q1 2025

May 14, 2025, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Annual report: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings release: Q4 2024

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Merlintrader Aug. 19 at 12:06 PM

0 · Reply

GoPatzGo123 Aug. 19 at 11:12 AM

$ONCY $MRNA just announced breakthrough in Cancer treatment

3 · Reply

GoPatzGo123 Aug. 19 at 11:11 AM

$MRNA wow $ONCY

0 · Reply

FoxM07 Aug. 19 at 8:00 AM

$ONCY

0 · Reply

cbachand Aug. 19 at 3:05 AM

$ONCY https://www.youtube.com/watch?v=1JMZGq9fxaU

0 · Reply

saxy4u Aug. 19 at 2:36 AM

2 · Reply

saxy4u Aug. 19 at 2:03 AM

$ONCY @FoxM07 unfortunately is blocked, can’t deal with them anymore. GL everyone, private message me if you need anything, sorry they ruined this board!

1 · Reply

saxy4u Aug. 19 at 2:02 AM

$ONCY @Noteable_Ex unfortunately is blocked! Sorry guys I can deal with them anymore!

0 · Reply

Notable_Ex Aug. 19 at 1:06 AM

$ONCY Hey spamman, where are you now?

0 · Reply

FoxM07 Aug. 18 at 11:24 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 11:23 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 11:22 PM

$ONCY

0 · Reply

Notable_Ex Aug. 18 at 11:20 PM

$ONCY Today's press release has outlined how the FDA had accelerated ONCY's registration and Accelerated/Full Approval strategy in MSS CRC by suggesting an EOP rather than a Type D meeting, thus bringing ONCY closer to a partnership or acquisition by Big Pharma. Conversely with an Accelerated Approval ONCY could conceivably go it alone, if necessary.

0 · Reply

FoxM07 Aug. 18 at 10:41 PM

$ONCY the exposed paid pumper not-able-x promised a part B CRC would run concurrently with part A to save time. He/she was wrong again & is lashing out.

1 · Reply

FoxM07 Aug. 18 at 10:39 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 10:39 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 10:39 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 10:39 PM

$ONCY

0 · Reply

Notable_Ex Aug. 18 at 10:29 PM

$ONCY

0 · Reply

Notable_Ex Aug. 18 at 10:04 PM

$ONCY In response to those lying bashers the ongoing REO 033 study is structured to transition directly from Part A into a pivotal Part B without the operational lag of launching an entirely new protocol from scratch - that happens under the FDA's single trial approval model which the FDA pivoted to on February 19, 2026. Part B start-up activities will emerge as positive interim data emerges this year. Meanwhile ONCY has derisked the MSS CRC registration pathway with the FDA's alignment on ONCY's single trial protocol.

0 · Reply

FoxM07 Aug. 18 at 8:46 PM

$ONCY

0 · Reply

FoxM07 Aug. 18 at 8:46 PM

$ONCY

0 · Reply

Market Cap	98.19M
Revenue (ttm)	0.00
Net Income (ttm)	-28.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	797,900
Avg Vol	1,244,788
Day's Range	N/A - N/A
Shares Out	119.35M
Stochastic %K	88%
Beta	1.13
Analysts	Strong Sell
Price Target	$5.25